Results 21 to 30 of about 76,081,297 (156)

Immuno-PET Imaging of Siglec-15 Using the Zirconium-89-Labeled Therapeutic Antibody, NC318

open access: yesMolecular Imaging, 2023
Objective. Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) is overexpressed in various cancers which has led to the development of therapeutic anti-Siglec-15 monoconal antibodies (mAbs).
Elaine M. Jagoda   +12 more
doaj   +2 more sources

Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma [PDF]

open access: yesFrontiers in Immunology, 2023
BackgroundSialic acid-binding immunoglobulin-like lectin-15 (Siglec-15) was reported to be a novel immune checkpoint molecule comparable to programmed cell death 1 ligand 1 (PD-L1).
Quan Chen   +9 more
doaj   +2 more sources

Siglec-15 and its glycan ligands in tumor-associated macrophage biology and immunotherapy [PDF]

open access: yesJournal for ImmunoTherapy of Cancer
Siglec-15 has recently emerged as an important regulator at the interface of glyco-immunology and cancer-immunology. The transmembrane immune receptor links cancer-associated glycosylation to immune suppression in the tumor microenvironment (TME). Siglec-
Romana T Netea-Maier   +6 more
doaj   +2 more sources

Prognostic value of Siglec-15 expression in patients with solid tumors: A meta-analysis [PDF]

open access: yesFrontiers in Oncology, 2023
BackgroundSiglec-15 is expressed in a variety of cancers. However, the role of Siglec-15 in the prognosis of cancer patients remains controversial. Therefore, we conducted a meta-analysis to clarify the potential prognostic value of Siglec-15 in solid ...
Kui-Ying Jiang   +5 more
doaj   +2 more sources

Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b [PDF]

open access: yesNature Communications, 2023
Sialic acid-binding Ig-like lectin 15 (Siglec-15) is an immune modulator and emerging cancer immunotherapy target. However, limited understanding of its structure and mechanism of action restrains the development of drug candidates that unleash its full ...
Maria Pia Lenza   +21 more
doaj   +2 more sources

Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma [PDF]

open access: yesScientific Reports, 2022
Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) might be involved in the activation of important pathways related to tumor immune escape, along with programmed death-ligand 1 (PD-L1).
Ju Zhao   +12 more
doaj   +2 more sources

Siglec-15 Promotes Tumor Progression in Osteosarcoma via DUSP1/MAPK Pathway [PDF]

open access: yesFrontiers in Oncology, 2021
Recurrence and metastasis are important features of osteosarcoma (OS) that cause its poor prognosis. Aberrant expression of Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) has been reported in various kinds of cancers.
Meng-ke Fan   +8 more
doaj   +2 more sources

Siglec-15-induced autophagy promotes invasion and metastasis of human osteosarcoma cells by activating the epithelial–mesenchymal transition and Beclin-1/ATG14 pathway [PDF]

open access: yesCell & Bioscience, 2022
Background Pulmonary metastasis is the main cause of poor prognosis in osteosarcoma. Sialic acid-bound immunoglobulin lectin 15 (Siglec-15) has been demonstrated to be obviously correlated with pulmonary metastasis in osteosarcoma patients.
Bingxin Zheng   +10 more
doaj   +2 more sources

Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes [PDF]

open access: yesFrontiers in Immunology, 2023
Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as Siglec-15. Presently, small molecule inhibitors targeting Siglec-15 are
Mohammed Saqif Ahmad   +5 more
doaj   +2 more sources

Prognostic significance of tumoral Siglec-15 expression in solid tumors: a systematic review and meta-analysis [PDF]

open access: yesFrontiers in Immunology
BackgroundSiglec-15 has emerged as a novel immune checkpoint molecule and a potential therapeutic target in solid tumors. Previous studies reported inconsistent prognostic significance of tumoral Siglec-15 expression across cancer types.
Ningning Zhang   +4 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy